Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
107 studies found for:    Hemophilia: Clinical Trials
Show Display Options
RSS Create an RSS feed from your search for:
Hemophilia: Clinical Trials
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: vatreptacog alfa (activated);   Drug: eptacog alfa (activated)
2 Completed Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: 40K PEG-rFIX
3 Active, not recruiting A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
4 Completed Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Interventions: Drug: activated recombinant human factor VII;   Drug: vatreptacog alfa (activated)
5 Completed Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
6 Completed Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
7 Completed Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
8 Completed Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
9 Active, not recruiting A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: BAY94-9027
10 Completed Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Drug: Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS
11 Completed Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
12 Completed Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Intervention: Drug: activated recombinant human factor VII, long acting
13 Active, not recruiting Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
14 Completed
Has Results
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
15 Completed Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
16 Completed Trial of NovoSeven® in Haemophilia - Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: activated recombinant human factor VII;   Drug: Feiba VH
17 Recruiting BAY81-8973 Pediatric Safety and Efficacy Trial
Condition: Haemophilia A
Intervention: Biological: Recombinant Factor VIII (BAY81-8973)
18 Completed A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
19 Completed
Has Results
Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
20 Active, not recruiting Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years